rabeprazole + levosulpiride

Rabeprazole + levosulpiride is a fixed-dose combination (FDC) therapy primarily utilized in the management of complex gastrointestinal disorders such as gastroesophageal reflux disease (GERD), functional dyspepsia, and irritable bowel syndrome. The combination pairs rabeprazole, a second-generation proton pump inhibitor (PPI), with levosulpiride, the levo-enantiomer of the substituted benzamide sulpiride. Rabeprazole acts by irreversibly inhibiting the H+/K+-ATPase enzyme system (the gastric proton pump) in the parietal cells, effectively suppressing both basal and stimulated gastric acid secretion. Levosulpiride functions as a selective antagonist of central and peripheral dopamine D2 receptors; in the gastrointestinal tract, this antagonism prevents the inhibitory effect of dopamine on cholinergic neurons, thereby increasing the release of acetylcholine. This prokinetic action enhances esophageal sphincter tone and accelerates gastric emptying. The synergy between acid suppression and improved motility makes this combination particularly effective for patients who do not respond adequately to PPI monotherapy.

Brand names

KRITCID-LRazle LRABOB-LSRabeloc PlusCyra-LSRabemac-LSVeloz-LRabicip-LHappi-LDrego-LS

Other names

rabeprazole sodium and levosulpiridelevosulpiride and rabeprazole